Wells Fargo Maintains Overweight on Synchrony Finl, Lowers Price Target to $45
Wells Fargo analyst Donald Fandetti maintains Synchrony Finl (NYSE:SYF) with a Overweight and lowers the price target from $52 to $45.
Related Posts
Rocket Pharmaceuticals Q4 EPS $(0.92) Misses $(0.80) Estimate; Cash, Cash Equivalents & Investments Of Approximately $400M With Operational Runway Expected Through 2024
Rocket Pharmaceuticals (NASDAQ:RCKT) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of $(0.80) by 15 percent. This is a 33.33 percent decrease over losses of $(0.69) per share
Medtronic Hugo Robotic-Assisted Surgery System Receives European CE Mark Approval
Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the Hugo™ robotic-assisted surgery (RAS) system,
Sonim Technologies Q3 EPS $(1.31) Down From $(1.00) YoY, Sales $14.45M Up From $14.39M YoY
Sonim Technologies (NASDAQ:SONM) reported quarterly losses of $(1.31) per share. This is a 31 percent decrease over losses of $(1.00) per share from the same period last year. The company reported $14.45 million in